SCHEMBL6991313

SCHEMBL6991313

CN(CCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1N)C1COC(=O)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 19/20 0.57
▸ KDR P35968 3/20 0.51
▸ ERBB2 P04626 6/20 0.50
▸ HDAC3 O15379 4/20 0.50
▸ HDAC4 P56524 4/20 0.50
▸ HDAC1 Q13547 4/20 0.50
▸ HDAC7 Q8WUI4 4/20 0.50
▸ HDAC2 Q92769 4/20 0.50
▸ HDAC10 Q969S8 4/20 0.50
▸ HDAC11 Q96DB2 4/20 0.50
▸ HDAC8 Q9BY41 4/20 0.50
▸ HDAC6 Q9UBN7 4/20 0.50
▸ HDAC9 Q9UKV0 4/20 0.50
▸ HDAC5 Q9UQL6 4/20 0.50
▸ FBP1 P09467 2/20 0.50
▸ AURKA O14965 1/20 0.49
▸ INSR P06213 1/20 0.49
▸ PDGFRB P09619 1/20 0.49
▸ FLT4 P35916 1/20 0.49
▸ CLK1 P49759 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6995705 0.96 EGFR (0.57) EGFRKDRERBB2FBP1AURKA
SCHEMBL7683735 0.89 EGFR (0.54) EGFR
SCHEMBL6988430 0.88 EGFR (0.57) EGFRKDRERBB2HDAC3HDAC4
SCHEMBL1384673 0.87 EGFR (0.70) EGFRKDRERBB2HDAC3HDAC4
SCHEMBL1383950 0.87 EGFR (0.70) EGFRKDRERBB2HDAC3HDAC4
SCHEMBL7690510 0.86 EGFR (0.65) EGFRKDRERBB2PDGFRBEPHB4
SCHEMBL6989473 0.85 EGFR (0.58) EGFRKDRERBB2HDAC3HDAC4
SCHEMBL7688337 0.85 EGFR (0.54) EGFRKDRFBP1
SCHEMBL4225530 0.84 EGFR (0.57) EGFRKDRERBB2FBP1EPHB4
SCHEMBL4226627 0.84 EGFR (0.57) EGFRKDRERBB2FBP1EPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1322645-A2 QUINAZOLINES, MEDICAMENTS, WHICH CONTAIN THESE COMPOUNDS AND WHICH ARE EFFECTIVE AS TYROSINE KINASE INHIBITORS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2003-07-02 — — EP disclosed
US-6403580-B1 HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES, THE USE THEREOF FOR TREATING DISEASES, PARTICULARLY TUMORAL DISEASES, DISEASES OF THE LUNGS AND RESPIRATORY TRACT, AND THE PREPARATION THEREOF. BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-06-11 — — US disclosed
WO-2002018375-A1 QUINAZOLINES, MEDICAMENTS, WHICH CONTAIN THESE COMPOUNDS AND WHICH ARE EFFECTIVE AS TYROSINE KINASE INHIBITORS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-03-07 — — WO disclosed
Send feedback